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Pandemic preparednessTen years after the launch of the Global Action Plan for Influenza Vaccines (GAP), the World Health
Organization (WHO) surveyed stakeholders to understand their perceptions of what the programme
had achieved. This article provides a summary of the findings; the full report will be available on-line
on the GAP website in November 2016 (http://www.who.int/influenza_vaccines_plan/en/). Seventy-
seven responses were received from stakeholders including medical doctors, national influenza center
officials, country immunization programme teams, surveillance and disease centers, policy-makers,
researchers, vaccine manufacturers, and non-governmental organizations from 28 countries, represent-
ing all six WHO regions.
Respondents cited GAP’s biggest successes as capacity building in developing countries; raising inter-
national awareness of global needs in the event of a pandemic; and collaborative alignment of influenza
stakeholders. The most commonly reported challenges were the limited progress in development of a
broadly protective or universal vaccine and the perceived absence of a major increase in seasonal
demand. These findings aligned with the perception that less global progress had been made under
the third GAP objective, focused on research and development of better vaccines, than on increasing sea-
sonal vaccine use (objective 1) and pandemic vaccine production capacity (objective 2). Respondents
explained what they saw as the major challenges to development of better vaccines, including to devel-
opment of a universal influenza vaccine. The majority of respondents agreed that the goal chosen at the
GAP II consultation is still relevant. Results highlighted the importance of promoting research and devel-
opment of better vaccines, both for facilitating uptake of seasonal vaccines and for ensuring timely
vaccine availability in the event of a pandemic. As the GAP concludes its mandate this year, these findings
will contribute to discussions on the impact of programme closure and how to address the key issues
facing influenza stakeholders thereafter.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Following the influenza A(H5N1) outbreak in 2005, there was
growing recognition that in the event of an influenza pandemic
there would be a global shortage of vaccines. In addition, produc-
tion capacity was concentrated in a few high income countries.
Resource-constrained countries would face delayed, limited and
possibly no access to vaccines. To address this, the World Health
Organization (WHO) convened a consultation in 2006 which
endorsed the Global Action Plan for Influenza Vaccines (GAP) [1].The GAP provided a comprehensive strategy to address global
scarcity and inequitable access to influenza vaccines in the event
of a pandemic, with three objectives [1]:
Objective 1: Increase evidence-based seasonal vaccine use.
Objective 2: Increase global pandemic vaccine production
capacity and strengthening national regulatory competencies.
Objective 3: Foster development of new influenza vaccines that
are not only higher-yielding and faster to produce, but also
inducing broader and longer protection.
The strategy was reviewed and updated at a global consultation
in 2011 [2].
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article offers insights into how government representatives, indus-
try leaders, researchers and public health professionals perceive its
successes and failures, as well as future actions that WHO and the
global community should consider during the discussions at the
final GAP consultation in November 2016. Stakeholder perceptions,
from both the public and private sectors, are important as they all
have key roles to play within the GAP framework [3]. Manufactur-
ers who received technology transfer and grants can provide
insightful input into the extent to which the GAP facilitated the
establishment of influenza vaccine production. Public health offi-
cials can comment on how WHO coordinated this intersectoral
approach with national authorities and on the needs and chal-
lenges of supporting policy implementation for influenza vaccina-
tion. Researchers can offer helpful perspectives on the R&D
landscape and associated challenges. Input from these stakehold-
ers provides a more holistic and accurate picture of the progress
made by the GAP.2. Methodology
WHO conducted an online survey between 16 December 2015
and 29 February 2016 [4]. Questions covered the following areas:
the relevance of the immunization goal agreed upon at the GAP
II consultation; the progress made with regards to the three GAP
objectives; the quality of data on diseases burden and vaccine
effectiveness; the factors influencing sustainable seasonal influ-
enza vaccine manufacturing and uptake; pandemic preparedness,
and progress in R&D. The survey was announced at several
influenza-related meetings and through direct mailings to the par-
ticipants of the first (2006) and second (2011) GAP consultations
[5], as well as to umbrella associations such as the International
Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) and the Developing Countries Vaccine Manufacturing Net-
work (DCVMN), and to members of the WHO Strategic Advisory
Group of Experts on Immunization (SAGE). The survey was also
posted on the WHO and International Society for Influenza and
Other Respiratory Virus Diseases (ISIRV) websites and advertised
in several newsletters.3. Survey questionnaire structure
The survey comprised a total of 22 questions including ques-
tions with yes/no answers, multiple-choice questions and open-
ended questions. To understand views on progress made under
the three GAP objectives multiple choice questions used a Likert
scale with the following ratings: very good, good, poor, and very
poor. Another type of multiple choice question was used to under-
stand perception of the importance of specific issues, where
numerical values were assigned for descriptive purposes as fol-
lows: very important, somewhat important, not important. This
scale was used to measure stakeholder perception of the impor-
tance of pandemic influenza vaccine availability and sustainable
influenza vaccine production. Unlike the Likert scale described
above, this measures the degree of importance for each factor,
rather than ratings above or below a neutral option. Although
the results may have been influenced by the choice of scale, they
are suitable for this survey which seeks to gauge the perceived rel-
ative importance of each factor, rather than the absolute impor-
tance of any single factor.
3.1. Analysis
Multiple-choice responses were converted into average scores
to increase comparability. For example, if a question asked respon-dents to choose whether a certain factor was ‘‘very important”,
‘‘somewhat important” or ‘‘not important”, answers were given
scores of 1, 0 and 1 respectively and averaged across the group.
The resulting average number was used to compare relative impor-
tance of a certain factor. Responses were also calculated and ana-
lyzed for sub-groups based on respondent characteristics such as
country of origin or field of work. Written responses were analyzed
by being read in detail to identify common themes, informative
points, and areas of strong opinion. We report here on a diverse
array of responses to ensure that several different points of view
are represented.4. Participants
Seventy-seven responses were received from respondents in 28
countries. Respondents did not answer every question; the least
answered question received 29 responses.
Fifty-eight percent of respondents represented the vaccine sup-
ply side: vaccine/pharmaceutical manufacturing (26%), vaccine
research (22%) and biotechnology (10%). The remaining respon-
dents were medical doctors, national influenza center officials
and other staff from surveillance and disease centers, national pol-
icy/planning departments, WHO collaborating centers, multilateral
organizations, country expanded programmes on immunization
(EPI) and non-governmental organizations. Of the fourteen manu-
facturers that received GAP funding to initiate a technology trans-
fer project, eleven participated in this survey.
Fifty-five percent of respondents were from high income coun-
tries, 28 percent from upper middle income countries, 16 percent
from lower middle income countries, and 1 percent from a low
income country (Fig. 1). All six WHO regions were represented,
with 34 percent from the Americas, 25 percent from Europe, 17
percent from the Western Pacific, 11 percent from South East Asia,
6 percent from the Eastern Mediterranean, and 4 percent from the
Africa region (Fig. 1). The remaining 3 percent identified them-
selves as working for global organizations.5. Key findings
This article presents an overview of a selection of the survey
questions and responses, as the complete analysis will be posted
on the WHO website before the consultation planned for Novem-
ber 2016 to mark the end of the ten years of the GAP [6]. The
answers presented in this article were chosen to provide a repre-
sentation of the views of a variety of the respondents (medical doc-
tors, manufacturers, national influenza center officials, policy
makers, NGOs, etc.).5.1. Relevance of GAP goal
The GAP II consultation, held in 2011, agreed that in order to
bring pandemic virus transmission under control, 70% of the global
population should be immunized with two doses of vaccine within
six months of the pandemic candidate vaccine virus being avail-
able, given the effects of herd immunity.
The survey asked whether this goal is still relevant. Of 74
responses received, the majority (84%) agreed that it was, and only
one disagreed (Fig. 2), the rest giving no opinion.5.2. Global progress made under the GAP
The survey asked respondents how they would rate global pro-
gress under each of the GAP’s three objectives (listed in the intro-
duction), as well as progress across all three objectives as a whole.
Fig. 1. Geographical distribution of respondents.
Fig. 2. Relevance of the goal agreed at the GAP II consultation.
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3 (Fig. 3). A third (33%) considered global progress under objective
3 to have been poor, and one respondent thought it very poor -
though several respondents felt that slow progress is to be
expected given the nature of universal vaccine development chal-
lenges. Objectives 1 and 2 were considered to have made better
progress: only an eighth of respondents for both objectives
(12.5%) though progress was poor, and none thought it very poor.
Respondents were similarly positive about overall progress across
the three objectives.
With respect to field of work, respondents representing vaccine
manufacturers were much more positive about progress towards
objective 3. Conversely, their view is relatively negative about pro-
gress under objective 2.6. Global progress made under GAP objectives 1, 2, and 3
Below is a summary of comments, both positive and negative,
that respondents used to justify their rating of the progress made
under the GAP:
Objective 1:
– Distribution and use of seasonal vaccines has been increasing at the
global level.Fig. 3. Global progress made– Awareness of influenza’s contribution to the overall disease burden
in many populations has been growing.
– Progress has been uneven - geographically and between sub-
populations.
– Barriers to progress in further uptake persist in developing coun-
tries due to competitive health priorities, high costs, healthcare
worker/public vaccination hesitancy, and low awareness.
Objective 2:
– Global production capacity has increased in terms of seasonal vac-
cines; the number of countries producing influenza vaccines; and
strengthening of National Regulatory Authorities. Some seasonal
influenza vaccines have received WHO pre-qualification status.
– Long-term sustainability is still questionable.
– Work remains to further streamline global activities and remove
barriers to facilitate vaccine release and distribution.
Objective 3:
– More novel vaccines are now in early and late stages of
development.
– Although high quality work has been carried out, there have not
been any substantial advances in the influenza vaccine field in
recent years (i.e. no ‘‘breakthrough discovery”).under GAP objectives.
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Respondents were asked what they saw as the GAP’s main suc-
cesses and shortcomings. Their responses are summarized in
Table 1, with the most common themes listed first.6.1.1. Perception of factors influencing progress on GAP Objective 1
Respondents were asked to rate the importance of different fac-
tors in terms of their role in facilitating the introduction and
uptake of seasonal influence vaccines. Fig. 4 ranks the factors in
order of importance based on the 58 responses received for this
question.Table 1
Perceived main successes and shortcomings of the GAP: summary table.
Successes Shortcomings
 Capacity building in developing
countries - both in terms of pro-
duction and National Regulatory
Authority strengthening
 Raising international awareness
in relation to the needs of the glo-
bal community in the event of a
pandemic
 Collaborative alignment of influ-
enza stakeholders in different
countries and sectors
 Increased global manufacturing
capacity
 Sharing evidence on the efficacy
and effectiveness of seasonal vac-
cination in various populations
 Assessing projected needs for
global pandemic vaccine
 Insufficient dedicated resources
to make a substantial and sus-
tained impact
 Limited progress in development
of a broadly protective or univer-
sal vaccine
 Failure to generate a major
increase in demand for seasonal
influenza vaccine
 Vaccine production capacity and
competencies are still in the
hands of a few and not yet spread
enough (i.e. to low and middle
income countries) to face a
pandemic
 Product registration processes
are still too slow
Fig. 4. Importance of factors for facilitating introduction and uptake of seasonal influ
important = 1).All of the factors listed in Fig. 4 were considered at least some-
what important by the majority of respondents. The availability of
better vaccines was considered the most important, while addi-
tional investment in activities to reduce vaccination hesitancy
was considered least important.
The summary provided by Fig. 4 masks some important differ-
ences of opinion between respondents from high and middle
income countries. In particular, when results are broken down by
income group it appears that, although cheaper vaccines are not
considered to be particularly important by respondents from high
income countries, the opposite picture prevails for upper and lower
middle income countries (Fig. 5). Respondents from lower middle
income countries also considered understanding of the disease
and economic burdens associated with influenza, and investment
in reducing vaccine hesitancy, to be more important for increasing
seasonal uptake.
6.1.2. Perception of factors influencing progress on GAP Objective 2
Survey participants were asked to rate the importance of sev-
eral factors and their effect in ensuring that additional production
capacity remains sustainable. The factor viewed as most important
was a demonstrated value proposition for influenza vaccine pro-
gramme investment in low and middle income countries (of 53
responses, 80% were ‘‘very important” and the rest ‘‘somewhat
important”). Conversely, the factor deemed least important was
the potential to export to other countries (49% of responses were
‘‘very important” and 6% did not think it was important at all).
Again, the breakdown of responses in Fig. 6 conceals some vari-
ation due to country income levels. For example, high income
countries ranked having functioning national regulatory agencies
and competitively priced vaccines as the least important. Yet, in
middle income countries these aspects were viewed as priorities.
Favourable procurement policies for locally produced vaccines also
divided opinion. Respondents from lower middle income countriesenza vaccines: average score (Very important = 1, Somewhat important = 0, Not
Fig. 5. Importance of factors for facilitating the introduction and uptake of seasonal influenza vaccines - by WB income status: average score (Not important = 1, Somewhat
important = 0, Very important = 1).
Fig. 6. Importance of factors for sustaining existing vaccine production capacity: average score (Very important = 1, Somewhat important = 0, Not important = 1).
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income countries put it second lowest.
As expected, there was also variation in survey responses with
regards to field of work. Respondents working in vaccine and phar-
maceutical production viewed favourable procurement policies as
more important than other respondents. Meanwhile, they viewed
availability of a more efficacious vaccine as less important relative
to other respondents.6.1.3. Perception of factors influencing progress on GAP Objective 3
The survey asked respondents to explain what they saw as the
major challenges to research and development of better vaccines
that elicit broader, longer lasting immune response, with respect
to regulatory science; scientific knowledge; financial availability;
intellectual property rights, and other factors. The 48 responses
highlighted the following challenges:6.1.3.1. Regulatory science.
 Finding a regulatory pathway based on T-cell mediated correlates
of protection, or more broadly, correlates beyond the
haemagglutination-inhibition (HAI) assay method which may not
be sufficient for testing new vaccine approaches.
 Clinical trial requirements may impose prohibitive time, informa-
tion and resource costs given the returns available from producing
influenza vaccines.
 Regulatory scrutiny in general presents a major challenge to timely
production of effective vaccines.
 Requirements to license vaccines with regulatory agencies in mul-
tiple countries.
6.1.3.2. Scientific knowledge.
 Recombinant vaccines have relatively weak immunogenicity and
require stronger adjuvants which are not yet licensed.
Fig. 7. Priorities for ensuring timely vaccine availability in the event of a pandemic: average score (Very important = 1, Somewhat important = 0, Not important = 1).
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ciently well understood. The major challenge is finding a ‘‘univer-
sal” antigen for a changing influenza virus. The antigens required
to develop a universal vaccine, or at least a vaccine with high cross
protection against similar subtypes, are hard to identify.
6.1.3.3. Financing.
 In the absence of strong profit incentives, research and develop-
ment of better influenza vaccines is dependent on government
and donor commitments. Short-term, intermittent funding can also
create challenges.
 The lack of a strong annual market for seasonal vaccines may
diminish industry investment.
 Influenza faces strong competition from other global health vaccine
challenges.
6.1.3.4. Intellectual property rights.
 Intellectual property rights are currently preventing full exploita-
tion of synthetic generation and the reverse genetics of influenza
viruses. Making reverse genetics accessible under more favourable
financial terms would be welcome.
 Although intellectual property rights are important for encouraging
innovation, they can also hamper technology transfer to low and
middle-income country manufacturers.
6.1.3.5. Other factors.
 Maintaining commitments towards influenza research despite the
frustration of recent years.
 Maintaining stakeholder collaboration.
6.2. Cross-cutting issues
Respondents were asked to rate the importance of steps to
ensure timely availability of sufficient pandemic influenza vac-
cines. On average, three factors stood out as priorities, as shown
in Fig. 7: promoting research and development of better vaccines;
a decision-making mechanism for switching from seasonal to pan-
demic production; and promoting research and development of a
universal influenza vaccine. Addressing vaccine hesitancy and gen-erating more studies on disease burden and vaccine effectiveness
were considered relatively unimportant in the event of a
pandemic.
7. Limitations
The low participation of lower middle and low income country
stakeholders is a limitation to the analysis, in particular the few
African respondents, and the fact that the supply side (industry
and research) was relatively well represented in relation to those
representing the users of vaccine. Only 4 percent of respondents
were from Africa, 12 percent from South East Asia, 17 percent from
the Western Pacific and 7 percent from the Eastern Mediterranean,
for a total of 40%. The European region and the region of the Amer-
icas counted for the majority of respondents (60%). Future surveys
should place a stronger emphasis on recruiting participants from
lower middle and low income countries.
The number of survey respondents is too low to permit infor-
mative statistical analysis of the results. However, this is not con-
sidered to be a major shortcoming since the results of this survey
were used for descriptive, not inferential, purposes, rather than
to demonstrate statistical significance. Therefore, the number of
respondents is deemed sufficient for the purposes of gauging key
GAP stakeholders’ opinions and contribute to the final GAP consul-
tation in November.
Furthermore, the survey was only available in the English lan-
guage, and in an-online, written format. Potential respondents
from other languages or who do not have good access to the inter-
net may have been deterred, though the majority of stakeholders
targeted are expected to have had adequate internet connectivity
and knowledge of English.
8. Conclusion
Full analysis of the perceptions obtained from this survey will
feed into discussions at the GAP consultation in November 2016,
where stakeholders will consider how funding and momentum
for ongoing projects in countries might be affected by the GAP’s
closure. Discussions will build on the findings that there is strong
agreement on the relevance of the goal agreed at the GAP II consul-
tation; and that relatively little global progress is perceived to have
been made under GAP objective 3. Discussions will be informed by
C. Nannei et al. / Vaccine 34 (2016) 5393–5399 5399a better understanding of stakeholder priorities, the successes and
challenges the GAP has faced, and barriers to future progress.
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